The abstract is read at the publisher; the summary is JClub's.
Triple therapy with dexamethasone, ABT-199, and the N-cadherin antagonist ADH-1 kills acute lymphoblastic leukaemia (ALL) cells in high-risk patient-derived xenograft-ALL samples.
- Why it matters: Cancer–microenvironment intercellular connections are linked to drug resistance, but their roles and how to disrupt them in bone marrow–like contexts remain insufficiently defined.
- What they did: The team built bone marrow–mimicking VAL hydrogel organoids using mesenchymal stroma cells and patient-derived ALL cells, then tested dexamethasone, ABT-199, and ADH-1 while tracking tunnelling nanotube (TNT)-like projections.
- The result: ALL therapies induced TNT-like projections between ALL cells and MSCs, and these were absent with ADH-1; combining dexamethasone, ABT-199, and ADH-1 was efficacious at killing ALL cells across different high-risk xenograft samples.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.